556 related articles for article (PubMed ID: 35514306)
1. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
[TBL] [Abstract][Full Text] [Related]
2. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
4. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
5. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
[TBL] [Abstract][Full Text] [Related]
6. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
8. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
[TBL] [Abstract][Full Text] [Related]
10. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
[TBL] [Abstract][Full Text] [Related]
11. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
13. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
14. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
[TBL] [Abstract][Full Text] [Related]
15. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
16. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
[TBL] [Abstract][Full Text] [Related]
17. Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022.
Atari N; Kliker L; Zuckerman N; Elkader BA; Weiss-Ottolenghi Y; Mendelson E; Kreiss Y; Regev-Yochay G; Mandelboim M
Euro Surveill; 2022 Nov; 27(44):. PubMed ID: 36330820
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022.
Kliker L; Zuckerman N; Atari N; Barda N; Gilboa M; Nemet I; Abd Elkader B; Fratty IS; Jaber H; Mendelson E; Alroy-Preis S; Kreiss Y; Regev-Yochay G; Mandelboim M
Euro Surveill; 2022 Jul; 27(30):. PubMed ID: 35904058
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
[TBL] [Abstract][Full Text] [Related]
20. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
